Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H25NO |
Molecular Weight | 271.3972 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3C)C2=C1
InChI
InChIKey=MKXZASYAUGDDCJ-CGTJXYLNSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21311876https://www.ncbi.nlm.nih.gov/pubmed/27139517Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876https://www.ncbi.nlm.nih.gov/pubmed/27139517
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584
Racemethorphan is racemic mixture of Dextromethorphan and Levomethorphan. Racemethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is therefore listed in the United States as a Controlled Substance, specifically as a Narcotic in Schedule II. Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive. Dextromethorphan is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Levomethorphan is an opioid analgesic of the morphinan family that has never been marketed.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24142584
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/16634036
Originator
Sources: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19480415&CC=CH&NR=254106A&KC=Ahttps://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19540415&CC=CH&NR=297994A&KC=A
Curator's Comment: # F. Hoffmann-La Roche & Co., A.-G.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345586 |
3360.0 nM [Ki] | ||
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15723099 |
205.0 nM [Ki] | ||
Target ID: CHEMBL4787 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2897648 |
|||
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345586 |
3360.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876 |
Primary | Unknown Approved UseUnknown |
||
PubMed
Title | Date | PubMed |
---|---|---|
The placebo response to citric acid-induced cough: pharmacodynamics and gender differences. | 2001 |
|
Pharmacological control of cough. | 2001 Apr |
|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
Angle closure risk from proprietary medicines. | 2001 Apr |
|
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. | 2001 Apr |
|
Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. | 2001 Apr 15 |
|
Characterization of biotransformation enzyme activities in primary rat proximal tubular cells. | 2001 Apr 16 |
|
A fast and efficient determination of amines and preservatives in cough and cold liquid and suspension formulations using a single isocratic ion-pairing high performance [correction of power] liquid chromatography method. | 2001 Aug |
|
CYP2D6 polymorphism in a Mexican American population. | 2001 Dec |
|
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. | 2001 Dec |
|
Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein. | 2001 Dec 1 |
|
The safety of dextromethorphan in pregnancy : results of a controlled study. | 2001 Feb |
|
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. | 2001 Jan |
|
Separation of cold medicine ingredients by capillary electrophoresis. | 2001 Jan |
|
Epidemiologic analysis of prenatal exposure to cough medicines containing dextromethorphan: no evidence of human teratogenicity. | 2001 Jan |
|
Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects. | 2001 Jan |
|
In vivo effect of clarithromycin on multiple cytochrome P450s. | 2001 Jul |
|
Clinical case discussion: anesthesia for Cesarean section in a parturient with a large intrathoracic tumour. | 2001 Jun |
|
Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. | 2001 Jun |
|
Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats. | 2001 Jun 29 |
|
Dextromethorphan is an effective cough suppressant. | 2001 May |
|
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. | 2001 May |
|
Effects of dextromethorphan on the seizures induced by kainate and the calcium channel agonist BAY k-8644: comparison with the effects of dextrorphan. | 2001 May |
|
Important drugs for cough in advanced cancer. | 2001 Nov |
|
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats. | 2001 Nov 5 |
|
Effects of dextromethorphan on nocturnal behavior and brain c-Fos expression in adolescent rats. | 2001 Nov 9 |
|
Abuse of Coricidin HBP cough & cold tablets: episodes recorded by a poison center. | 2001 Oct 1 |
|
Analgesic effects of dextromethorphan and morphine in patients with chronic pain. | 2002 Apr |
|
Modulation of human corticomotor excitability by somatosensory input. | 2002 Apr 15 |
|
Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes. | 2002 Feb |
|
Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys. | 2002 Feb |
|
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. | 2002 Jan |
|
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. | 2002 Jan |
|
Effect of ketamine, dextromethorphan, and MK-801 on cochlear dysfunction induced by transient ischemia. | 2002 Jan |
|
Dextromethorphan can produce false positive phencyclidine testing with HPLC. | 2002 Jan |
|
Inhibition kinetics of monoclonal antibodies against cytochromes P450. | 2002 Jun |
|
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. | 2002 Jun |
|
Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. | 2002 Mar 1 |
|
The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6. | 2002 May |
|
Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. | 2002 May |
|
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. | 2002 May |
|
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. | 2002 May 11 |
|
Semi-automated liquid--liquid back-extraction in a 96-well format to decrease sample preparation time for the determination of dextromethorphan and dextrorphan in human plasma. | 2002 May 25 |
|
Ubiquitous computing for remote cardiac patient monitoring: a survey. | 2008 |
|
Effects of common antitussive drugs on the hERG potassium channel current. | 2008 Dec |
|
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. | 2009 Apr 1 |
|
Amyotrophic lateral sclerosis. | 2009 Feb 3 |
|
Characterization of retrieved orthodontic miniscrew implants. | 2009 Jan |
|
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. | 2009 Jan |
|
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy. | 2009 Jan-Feb |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876
Levomethorphan (dissolved in a mixed solution of 5% Emulphor™ EL-620/5% ethanol/90% isotonic sodium chloride solution, 2.5 mg/mL, rat 4–6) was administered to male DA pigmented rats, which were 5 weeks old and around 90 g mean weight. The drugs were given once daily at 5 mg/kg by intraperitoneal injection for ten successive days.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21311876
Liver microsomes from individual male dark agouti (DA) rats (n=4, 6 weeks old, around 125 g mean weight) were prepared by ultracentrifugation. For the in vitro experiments with rat and human liver microsomes, the reaction mixture consisted of 0.1 M potassium phosphate buffer (pH 7.4) with an NADPH generating system (1.3 mM NADP, 3.3 mM G-6-P, 0.4 U/ mL G-6-PDH, 3.3 mM MgCl2), 50 μM substrate (dextromethorphan or levomethorphan), and 0.5 mg protein/mL microsomes (rat or human liver microsomes) in a final volume of 200 μL. Dextromethorphan and levomethorphan were dissolved in methanol, and the final concentration of the organic solvent was 0.1%. The incubation was started by adding the microsomal fraction and then continued for 0, 5, 10, or 20 min. The reaction was terminated by adding an equal volume of a mixed organic solution of 50% acetonitrile and 50% methanol, including 10 μM levallorphan (IS), and vigorous shaking.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
||
|
DEA NO. |
9210
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08478MIG
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
LEVOMETHORPHAN
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
148
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
146176
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
C83875
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
204-751-7
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
DTXSID20872403
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
7ZZ22K9QE6
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
CHEMBL1908323
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
m6790
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000082278
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
125-70-2
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
5362449
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY | |||
|
1362359
Created by
admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)